WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising a member selected from the group consisting of:

(a) a polynucleotide encoding the polypeptide comprising amino acid 1 to amino acid 168 as set forth in SEQ ID NO:2;

(b) a polynucleotide which encodes a mature polypeptide having the amino acid sequence expressed by the DNA contained in ATCC Deposit No. _____;

(c) a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a) or (b); and

(d) a polynucleotide fragment of the polynucleotide of (a), (b) or (c).

2. The polynucleotide of claim 1 which encodes a mature polypeptide having the amino acid sequence expressed by the DNA contained in the EMAR III deposited clone.

3. The polynucleotide of Claim 1 wherein the polynucleotide is DNA.

4. The polynucleotide of Claim 2 which encodes the polypeptide comprising amino acid 1 to 168 of SEQ ID NO:2.

5. The polynucleotide of claim 1 comprising the sequence as set forth in SEQ ID No. 1 from nucleotide 1 to nucleotide 636.

6. The polynucleotide of claim 1 comprising the sequence as set forth in SEQ ID No. 1 from nucleotide 94 to nucleotide 636.

7. The polynucleotide of claim 1 comprising the sequence as set forth in SEQ ID No. 1 from nucleotide 94 to nucleotide 600.

8. A vector containing the DNA of Claim 2.

9. A host cell genetically engineered with the vector of Claim 8.

10. A process for producing a polypeptide comprising: expressing from the host cell of Claim 9 the polypeptide encoded by said DNA.

11. A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of Claim 8.

12. A polypeptide comprising a member selected from the group consisting of (i) a polypeptide having the deduced amino acid sequence of SEQ ID NO:2 and fragments, analogs and derivatives thereof; and (ii) a polypeptide encoded by the cDNA of ATCC Deposit No. ____ and fragments, analogs and derivatives of said polypeptide.

13. The polypeptide of Claim 12 wherein the polypeptide comprises amino acid 1 to amino acid 168 of SEQ ID NO:2.

14. A compound which activates the receptor of the polypeptide of claim 12.

15. An antibody against the polypeptide of claim 12.

16. A method for the treatment of a patient having need of EMAP III comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 12.

17. The method of Claim 16 wherein said therapeutically effective amount of the polypeptide is administered by

providing to the patient DNA encoding said polypeptide and expressing said polypeptide *in vivo*.

18. A process for diagnosing a disease or a susceptibility to a disease related to an under-expression of the polypeptide of claim 12 comprising:

determining a mutation in a nucleic acid sequence encoding said polypeptide.

19. A diagnostic process comprising:

analyzing for the presence of the polypeptide of claim 12 in a sample derived from a host.

20. A method for identifying compounds which bind to and activate the receptor of the polypeptide of claim 12 comprising:

contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with an analytically detectable compound under conditions to permit binding to the receptor; and

determining whether the compound binds to and activates the receptor by detecting the presence of the signal.

ADD A4

add E1

add F3

add B1